These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37333918)

  • 21. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
    Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
    Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.
    Ng J; Rosenblat JD; Lui LMW; Teopiz KM; Lee Y; Lipsitz O; Mansur RB; Rodrigues NB; Nasri F; Gill H; Cha DS; Subramaniapillai M; Ho RC; Cao B; McIntyre RS
    J Affect Disord; 2021 Oct; 293():285-294. PubMed ID: 34225208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ketamine for Treatment-Resistant Mood Disorders.
    Park LT; Falodun TB; Zarate CA
    Focus (Am Psychiatr Publ); 2019 Jan; 17(1):8-12. PubMed ID: 31975953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal esketamine: From origins to future implications in treatment-resistant depression.
    Sanders B; Brula AQ
    J Psychiatr Res; 2021 May; 137():29-35. PubMed ID: 33647726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Esketamine for treatment‑resistant depression: A review of clinical evidence (Review).
    Vasiliu O
    Exp Ther Med; 2023 Mar; 25(3):111. PubMed ID: 36793329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study.
    Rothärmel M; Benosman C; El-Hage W; Berjamin C; Ribayrol D; Guillin O; Gaillard R; Berkovitch L; Moulier V
    Front Psychiatry; 2022; 13():865466. PubMed ID: 35873243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression.
    Tamman A; Anand A; Mathew SJ
    Expert Opin Drug Saf; 2022 Jun; 21(6):745-759. PubMed ID: 35253555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine.
    Garakani A
    J Psychiatr Pract; 2021 Nov; 27(6):496-497. PubMed ID: 34768276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study).
    Martinotti G; Vita A; Fagiolini A; Maina G; Bertolino A; Dell'Osso B; Siracusano A; Clerici M; Bellomo A; Sani G; d'Andrea G; Chiaie RD; Conca A; Barlati S; Di Lorenzo G; De Fazio P; De Filippis S; Nicolò G; Rosso G; Valchera A; Nucifora D; Di Mauro S; Bassetti R; Martiadis V; Olivola M; Belletti S; Andriola I; Di Nicola M; Pettorruso M; McIntyre RS; di Giannantonio M;
    J Affect Disord; 2022 Dec; 319():646-654. PubMed ID: 36167246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report.
    Matteo M; Cristian P; Laura M; Federico M; Chiara R; Lorenzo G; Michaela K; Sibilla M; Roberto N; Fabrizia C; Antonios D; Alice C; Enrico C; Beatrice B; Francesca B; Nicoletta V; Alberto P; Silvia I; Massimo C
    Ann Gen Psychiatry; 2021 Sep; 20(1):43. PubMed ID: 34530843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study.
    Araújo-de-Freitas L; Santos-Lima C; Mendonça-Filho E; Vieira F; França RJAF; Magnavita G; Cardoso TL; Correia-Melo FS; Leal GC; Jesus-Nunes AP; Souza-Marques B; Marback R; Teles M; Echegaray MV; Beanes G; Guerreiro-Costa LNF; Mello RP; Rabanea T; Lucchese AC; Abreu N; Lacerda ALT; Quarantini LC
    Psychiatry Res; 2021 Sep; 303():114058. PubMed ID: 34153630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme.
    Samalin L; Rothärmel M; Mekaoui L; Gaudré-Wattinne E; Codet MA; Bouju S; Sauvaget A
    Int J Psychiatry Clin Pract; 2022 Nov; 26(4):352-362. PubMed ID: 35174754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
    Sukhram SD; Yilmaz G; Gu J
    Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
    Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K
    Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intranasal Ketamine for Depression in Adults: A Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials.
    An D; Wei C; Wang J; Wu A
    Front Psychol; 2021; 12():648691. PubMed ID: 34140915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant.
    Floden L; Hudgens S; Jamieson C; Popova V; Drevets WC; Cooper K; Singh J
    CNS Drugs; 2022 Jun; 36(6):649-658. PubMed ID: 35441931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study.
    Cullen KR; Amatya P; Roback MG; Albott CS; Westlund Schreiner M; Ren Y; Eberly LE; Carstedt P; Samikoglu A; Gunlicks-Stoessel M; Reigstad K; Horek N; Tye S; Lim KO; Klimes-Dougan B
    J Child Adolesc Psychopharmacol; 2018 Sep; 28(7):437-444. PubMed ID: 30004254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study.
    Smith-Apeldoorn SY; Veraart JKE; Ruhé HG; Aan Het Rot M; Kamphuis J; de Boer MK; Schoevers RA
    BJPsych Open; 2021 Dec; 8(1):e4. PubMed ID: 34865676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.